|
Bulgaria Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The Bulgaria Pharmaceuticals and Healthcare Report
Independent 5-year pharmaceutical and healthcare industry forecasts for Bulgaria.
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Bulgarian pharmaceutical and healthcare industry.
Competitive intelligence, Bulgarian pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Bulgarian market.
The Bulgaria Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Business Monitor International’s Bulgaria Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Bulgarian pharmaceutical and healthcare industry.
Key Benefits of Report
- Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Bulgaria to test other views – a key input for successful budgeting and strategic business planning in the Bulgarian pharmaceutical and healthcare market.
- Target Business Opportunities & Risks in the Bulgarian Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Bulgaria.
- Exploit The Latest Competitive Bulgarian Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in Bulgaria.
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
BMI 5-Year Industry Forecast
5-Year Forecasts to end- for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
- Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
- Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
- OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
- Generics market (US$bn)/ as % of total market
- Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
BMI 5-Year Macroeconomic Forecasts
BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
|
Bulgaria Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Chapter - Executive Summary |
| Bulgaria Pharmaceuticals And Healthcare SWOT |
| Bulgaria Political SWOT |
| Bulgaria Economic SWOT |
| Bulgaria Business Environment SWOT |
Chapter - Pharmaceutical Business Environment Ratings |
| Table: Central and Eastern Europe Pharmaceuticals & Healthcare Business Environment Rating For Q209 |
| Limits Of Potential Returns |
| Risks To Realisation Of Returns |
Chapter - Bulgaria – Market Summary |
| Regulatory Regime |
| Recent Regulatory Developments |
| Intellectual Property Environment |
| Intellectual Property Deficiencies |
| Corruption And Counterfeit Drugs |
| Pricing Regime |
| Table: Wholesale Mark-Ups |
| Table: Retail Mark-Ups |
| Reimbursement Regime |
| Recent Pricing And Reimbursement Developments |
Chapter - Industry Developments |
| Epidemiology |
| Table: Main Causes Of Death In Bulgaria (per 100,000 population |
| Table: Disease Burden In CEE |
| Healthcare Sector |
| National Healthcare Plan |
| Healthcare Insurance |
| Recent Healthcare Insurance Developments |
| Healthcare Debt |
| Hospital Privatisation Programme |
| Healthcare Information System |
| Introduction Of Patient E-Cards |
Chapter - Industry Forecast Scenario |
| Overall Market Forecast |
| Table: Pharmaceutical Market Indicators (US$mn unless otherwise stated) |
| Key Growth Factors – Industry |
| Table: Health Expenditure Indicators |
| Macroeconomic Forecast Scenario |
| Table: Bulgaria - Economic Activty |
| Prescription Market Forecast |
| Table: Prescription Market Indicators (US$mn unless otherwise stated) |
| Patented Market Forecast |
| Table: Patented Market Indicators (US$mn unless otherwise stated) |
| Generics Market Forecast |
| Table: Generics Market Indicators |
| OTC Market Forecast |
| Table: OTC Market Indicators (US$mn unless otherwise stated) |
| Export/Import Market Forecasts |
| Table: Pharmaceutical Trade Indicators (US$mn) |
| Medical Device Forecast |
| Table: Classification Of Medical Devices In The EU |
| Table: Bulgaria Medical Device Market Forecast |
| Other Healthcare Data Forecasts |
| Table: Other Healthcare Data Forecasts |
| Key Risks To BMI's Forecast Scenario |
Chapter - Competitive Landscape |
| Table: Top 10 Products In Bulgaria By Sales, 2006 |
| Local Pharmaceutical Industry |
| Foreign Pharmaceutical Industry |
| Recent Industry Developments |
| Wholesale Sector |
| Retail Sector |
| Research And Development |
| Clinical Trials |
Chapter - Company Monitor |
| Foreign Companies |
| GlaxoSmithKline |
| Novartis |
| Sanofi-Aventis |
| Pfizer |
| Merck & Co |
| Indigenous Companies |
| Actavis Bulgaria (formerly Balkanpharma) |
| Sopharma |
| Biovet |
Chapter - Country Snapshot: Bulgaria Demographic Data |
| Section 1: Population |
| Table: Demographic Indicators, 2005-2030 |
| Table: Rural/Urban Breakdown, 2005-2030 |
| Section 2: Education And Healthcare |
| Table: Education, 2002-2005 |
| Table: Vital Statistics, 2005-2030 |
| Section 3: Labour Market And Spending Power |
| Table: Employment Indicators, 2001-2006 |
| Table: Consumer Expenditure, 2000-2012 (US$) |
| Table: Average Annual Wages, 2000-2012 |
Chapter - BMI Forecast Modelling |
| How We Generate Our Pharmaceutical Industry Forecasts |
| Pharmaceutical Business Environment Ratings Methodology |
| Ratings Overview |
| Table: Pharmaceutical Business Environment Indicators |
| Weighting |
| Table: Weighting Of Components |
| Sources |
|
Bulgaria Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The Bulgarian pharmaceutical market, like many others, underwent significant reform before, during and after EU accession. While the country remains one of the least developed in the EU both economically and in terms of healthcare, market reform looks set to boost patient access to medicines as well as pharmaceutical company sales in medium term. Following low single-digit growth in 2005 and 2006, sales increased substantially during 2007 and 2008. Over the next five years, sales of pharmaceuticals – which include prescription drugs and over-the-counter medicines – will increase from US$1.09bn to US$1.56bn at constant exchange rates, representing a compound annual growth rate (CAGR) of 7.45%.
In BMI’s Pharmaceutical Business Environment Rankings for Q209, Bulgaria occupies 12th place (out of 20) in Central and Eastern Europe (CEE) and 43rd (out of 71) globally. While sales growth has picked up in recent years, it remains below many other markets in CEE. The relatively small market, and per capita spending of only US$143 in 2008, limits potential for multinational drugmakers. Furthermore while regulations have improved in the last two years, they remain less developed than in fellow EU members. Access to innovation also remains a key challenge in Bulgaria.
Bulgaria’s health system has been in the process of reform for many years. However, the crucial aspect of re-addressing health funding has yet to be completed. This issue is to be delayed again, until after June 2009, when the next government comes into power. Ruling coalition party, the Bulgarian Socialist Party (BSP), plans to carry out a regional re-evaluation of healthcare systems in Western Europe in order to devise a new model, which will take more time than initially anticipated, according to Todor Kunchev, deputy director of the parliamentary health commission.
As part of Bulgaria’s reform plans, the Ministry of Health has also introduced a bill to create a medical inspectorate. Comprised of patient representatives and healthcare professionals, the inspectorate would be responsible for supervising expenditure and improving quality and efficiencies within individual facilities.
Pharmaceutical trade has seen a massive growth over the last two years. EU accession in 2007, for example, saw triple digit growth in the export sector. Bulgaria’s low cost base is a major advantage for multinationals. EU membership has aided this somewhat, although the largest increases have been witnessed in exports to Russia over the past three years.
Despite restructuring its manufacturing operations in early 2009, leading drugmaker Actavis reaffirmed its commitment to Bulgaria with the investment of around EUR60mn in two production lines in the company’s plant in Dupnitsa.
|
Bulgaria Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Africa |
| Algeria, Egypt, Kenya, Morocco, Nigeria, South Africa and Zimbabwe |
Asia |
| Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam |
Caribbean |
| Puerto Rico |
Europe |
| Belarus, Belgium, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Italy, Kazakhstan, Latvia, Lithuania, Moldova, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Switzerland, Ukraine, United Kingdom and Uzbekistan |
Latin America |
| Argentina, Brazil, Chile, Colombia, Mexico, Peru and Venezuela |
Middle East |
| Bahrain, Iran, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Turkey and United Arab Emirates |
North America |
| Canada and United States |
Business Monitor InternationalA Market Leader in Country Risk, Industry Intelligence and Company Research Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK |
BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world. Country Risk Analysis and Forecasts Industry Intelligence and Market Research Company Research |